Skip to Content

What is the difference between Renflexis and Remicade?

Answers (1)

Official Answer by Drugs.com 5 Jul 2017

Renflexis (infliximab-abda) is a tumor necrosis factor (TNF) blocker from Samsung Bioepis that is biosimilar to Remicade (infliximab), from Janssen Biotech. According to the FDA, a biosimilar must be shown to have no clinically meaningful differences in terms of safety and effectiveness from the reference product -- in this case Remicade.

Only minor differences in clinically inactive components are allowable in biosimilar products. Renflexis is given as an intravenous infusion similar to Remicade, and is indicated for the same indications, specifically treatment of Crohn disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. The first biosimilar to Remicade, Pfizer’s Inflectra (infliximab-dyyb) was approved by the FDA in April, 2016.

See also: https://www.drugs.com/compare/remicade-vs-renflexis

Drugs.com free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

What type of drug is Motegrity?

Updated 18 days ago 1 answerFAQ by Drugs.com

What disease is Elzonris (tagraxofusp-erzs) used to treat?

Updated 15 days ago 1 answerFAQ by Drugs.com

How do you use the ProAir Digihaler?

Updated 15 days ago 1 answerFAQ by Drugs.com

How many biosimilars have been approved in the United States?

Updated 14 days ago 1 answerFAQ by Drugs.com